Remarks: What Would the Saudi Arabian Ministry of Health Know About Using Hydroxychloroquine to Treat COVID Patients ? CLEARLY FOR MORE THAN Australia’s Prime Minister Scott Morrison, MoH Greg Hunt MP, DoH Secretary Brendan Murphy, Acting Chief Medical Officer Paul Kelly & Deputy Chief Medical Officer Dr Nick Coatsworth. FULL STORY HERE: https://www.4cmitv.com/2020/09/13/2020-sep-13-hcq-saudis-moh-vs-australian-moh-clearly-saudis-moh-are-not-killing-their-citizens-with-covid-19/
These Australian Government bureaucrats who continue to prop up the unscientific interference between Practitioner and Patient concerning the use of HCQ in treatment of COVID 19. This unscientifically based stonewall they’ve placed runs contrary to more than 65 studies which demonstrate HCQ (Hydroxychloroquine) used with Zinc is very effective companion medication therapy especially when taken in the early stage of COVID 19 infection; Studies have clearly demonstrated using this treatment regime massively reduces Hospitalisation and Mortality.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxSaudi Arabia exert full treatment flow chart here
Crag Kelly MP:
CASE FATALITY RATE[1]deaths/positive tests for COVID
Saudi Arabia: 1.3%
Australia: 3%
Victoria AU: 4%
The official government protocol to treat COVID patients in Saudi Arabia includes Hydroxychloroquine (HCQ) and Zinc. See below: 10.1101/2020.09.09.20184143
In Australia our health bureaucrats believe they know better and Australian COVID patients are denied access to HCQ – and it’s illegal for Australian doctors to prescribe it.
In Saudi Arabia, the case fatality rate (deaths/positive tests) for COVID is 1.3%
In Australia it’s 3%. In Victoria it’s 4%.
In other words, in Australia (where HCQ is banned) if you get COVID, you are more than twice as likely to die than in Saudi Arabia (where HCQ + Zinc is standard treatment).
I wonder how many lives the Hydroxychloroquine deniers club are responsible for so far ?
click on image to enlarge
Tarek Sulaiman[2]Tarek Sulaiman, King Fahad Medical City, Riyadh, Saudi Arabia; Abdulrhman Mohana[3]Abdulrhman Mohana, Saudi Center for Disease Prevention and Control; Laila Alawdah[4]Laila Alawdah, King Fahad Medical City, Riyadh, Saudi Arabia; Nagla Mahmoud[5]Nagla Mahmoud, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Mustafa Hassanein[6]Mustafa Hassanein, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Tariq Wani[7]Tariq Wani, King Fahad Medical City, Riyadh, Saudi Arabia; Amel Alfaifi[8]Amel Alfaifi, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Eissa Alenazi[9]Eissa Alenazi, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Nashwa Radwan[10]Nashwa Radwan, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Nasser AlKhalifah[11]Nasser AlKhalifah, King Fahad Medical City, Riyadh. Saudi Arabia; Ehab Elkady[12]Ehab Elkady, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Manwer AlAnazi[13]Manwer AlAnazi, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Mohammed Alqahtani[14]Mohammed Alqahtani, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Khalid Abdalla[15]Khalid Abdalla, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Yousif Yousif[16]Yousif Yousif, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Fouad AboGazalah[17]Fouad AboGazalah, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Fuad Awwad[18]Fuad Awwad, Quantitative analysis department, College of Business Administration, King Saud University, Riyadh, Saudi Arabia; Khaled AlabdulKareem[19]Khaled AlabdulKareem, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia; Fahad AlGhofaili[20]Fahad AlGhofaili, King Fahad Medical City, Riyadh. Saudi Arabia; Ahmed AlJedai[21]Ahmed AlJedai, Assistant Deputy Minister for Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia; Hani Jokhdar[22]Hani Jokhdar, Deputyship of Public Health, Ministry of Health, Riyadh, Saudi Arabia; Fahad Alrabiah[23]Fahad Alrabiah, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
ABSTRACT
METHODS:
This observational prospective cohort study took place in 238 ambulatory fever clinics in Saudi Arabia, which followed the Ministry of Health (MOH) COVID-19 treatment guideline.
This guideline included multiple treatment options for COVID-19 based on the best available evidence at the time, among which was Hydroxychloroquine (HCQ).
Patients with confirmed COVD-19 (by reverse transcriptase polymerase chain reaction (PCR) test) who presented to these clinics with mild to moderate symptoms during the period from 5-26 June 2020 were included in this study.
Our study looked at those who received HCQ-based therapy along with supportive care (SC) and compared them to patients who received SC alone.
The primary outcome was hospital admission within 28-days of presentation.
The secondary outcome was a composite of intensive care admission (ICU) and/or mortality during the follow-up period. Outcome data were assessed through a follow-up telephonic questionnaire at day 28 and were further verified with national hospitalisation and mortality registries.
Multiple logistic regression model was used to control for prespecified confounders.
RESULTS:
Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever clinics during the study period, 5,541 had verified clinical outcomes at day 28 (1,817 patients in the HCQ group vs 3,724 in the SC group).
At baseline, patients who received HCQ therapy were more likely to be males who did not have hypertension or chronic lung disease compared to the SC group.
No major differences were noted regarding other comorbid conditions. All patients were presenting with active complaints; however, the HCQ groups had higher rates of symptoms compared to the SC group (fever: 84% vs 66.3, headache: 49.8 vs 37.4, cough: 44.5 vs 35.6, respectively).
Early HCQ-based therapy was associated with a lower hospital admission within 28-days compared to SC alone (9.4% compared to 16.6%, RRR 43%, p-value <0.001).
The composite outcome of ICU admission and/or mortality at 28-days was also lower in the HCQ group compared to the SC (1.2% compared to 2.6%, RRR 54%, p-value 0.001).
Adjusting for age, gender, and major comorbid conditions, a multivariate logistic regression model showed a decrease in the odds of hospitalisation in patients who received HCQ compared to SC alone (adjusted OR 0.57 [95% CI 0.47-0.69], p-value <0.001).
The composite outcome of ICU admission and/or mortality was also lower for the HCQ group compared to the SC group controlling for potential confounders (adjusted OR 0.55 [95% CI 0.34-0.91], p-value 0.019).
CONCLUSION:
Early intervention with HCQ-based therapy in patients with mild to moderate symptoms at presentation is associated with lower adverse clinical outcomes among COVID-19 patients, including hospital admissions, ICU admission, and/or death.
2020.09.09.20184143v1.full
Hashtags: #4cminewswire, #HCQ, #Australia, #SaudiArabia, #ScottMorrison, #GregHunt, #BrendanMurphy, #PaulKelly, #NickCoatsworth, #COVID19, #4cminews, #4CMiTV, #4CM2020SEP13,
Tags: 4cminewswire, HCQ, Australia, Saudi Arabia, Scott Morrison, Greg Hunt, Brendan Murphy, Paul Kelly, Nick Coatsworth, COVID-19, 4cminews, 4CMiTV, #4CM2020SEP13,
4CMINEWS SOCIAL MEDIA:
Gab: https://gab.com/4cminewswire/posts/104868268533491767
Gab AU: https://gab.com/4cminewswire/posts/104868263020954641
Telegram: @Newswire4cm
Twitter: https://twitter.com/4cminews/status/1305817483459194880?s=20
Parler: https://share.par.pw/post/fb3a53ec6ffb46428935655b1af91808
Dailymotion & Facebook: DEFUNCT SOCIAL MEDIA PLATFORM
.
.
Situation Vacant
References
| ↑1 | deaths/positive tests |
|---|---|
| ↑2 | Tarek Sulaiman, King Fahad Medical City, Riyadh, Saudi Arabia |
| ↑3 | Abdulrhman Mohana, Saudi Center for Disease Prevention and Control |
| ↑4 | Laila Alawdah, King Fahad Medical City, Riyadh, Saudi Arabia |
| ↑5 | Nagla Mahmoud, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑6 | Mustafa Hassanein, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑7 | Tariq Wani, King Fahad Medical City, Riyadh, Saudi Arabia |
| ↑8 | Amel Alfaifi, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑9 | Eissa Alenazi, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑10 | Nashwa Radwan, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑11 | Nasser AlKhalifah, King Fahad Medical City, Riyadh. Saudi Arabia |
| ↑12 | Ehab Elkady, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑13 | Manwer AlAnazi, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑14 | Mohammed Alqahtani, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑15 | Khalid Abdalla, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑16 | Yousif Yousif, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑17 | Fouad AboGazalah, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑18 | Fuad Awwad, Quantitative analysis department, College of Business Administration, King Saud University, Riyadh, Saudi Arabia |
| ↑19 | Khaled AlabdulKareem, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia |
| ↑20 | Fahad AlGhofaili, King Fahad Medical City, Riyadh. Saudi Arabia |
| ↑21 | Ahmed AlJedai, Assistant Deputy Minister for Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia |
| ↑22 | Hani Jokhdar, Deputyship of Public Health, Ministry of Health, Riyadh, Saudi Arabia |
| ↑23 | Fahad Alrabiah, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia |